Abstract
The concept of nonsynaptic communication between neurons, once a heretic idea, has become a self-evident fact during the almost forty years since its original discovery [1]. In this review we investigate whether the archetypical synaptic transmitters of the central nervous system, Glu and GABA, can operate via nonsynaptic transmission. While experimental data supporting the general concept of nonsynaptic transmission has been progressively accumulating during these years, most of the evidence regarding nonsynaptic transmission by Glu and GABA are results of the last decade. In this paper we collect evidence for different forms of nonsynaptic transmission by the Gluergic and GABAergic system. We investigate two theoretical predictions of the concept of nonsynaptic transmission in the light of recent progress in the field: i) since extrasynaptic receptors experience a lower concentration of agonist, they are likely to have higher affinity for the agonist ii) extrasynaptic receptors are expected to be more important pharmacological targets.
Keywords: Glu spillover, phasic and tonic GABA spillover, ambient Glu and GABA, concept of nonsynaptic transmission
Current Topics in Medicinal Chemistry
Title: Nonsynaptic Receptors for GABA and Glutamate
Volume: 6 Issue: 10
Author(s): E. S. Vizi and Arpad Mike
Affiliation:
Keywords: Glu spillover, phasic and tonic GABA spillover, ambient Glu and GABA, concept of nonsynaptic transmission
Abstract: The concept of nonsynaptic communication between neurons, once a heretic idea, has become a self-evident fact during the almost forty years since its original discovery [1]. In this review we investigate whether the archetypical synaptic transmitters of the central nervous system, Glu and GABA, can operate via nonsynaptic transmission. While experimental data supporting the general concept of nonsynaptic transmission has been progressively accumulating during these years, most of the evidence regarding nonsynaptic transmission by Glu and GABA are results of the last decade. In this paper we collect evidence for different forms of nonsynaptic transmission by the Gluergic and GABAergic system. We investigate two theoretical predictions of the concept of nonsynaptic transmission in the light of recent progress in the field: i) since extrasynaptic receptors experience a lower concentration of agonist, they are likely to have higher affinity for the agonist ii) extrasynaptic receptors are expected to be more important pharmacological targets.
Export Options
About this article
Cite this article as:
Vizi S. E. and Mike Arpad, Nonsynaptic Receptors for GABA and Glutamate, Current Topics in Medicinal Chemistry 2006; 6 (10) . https://dx.doi.org/10.2174/156802606777323782
DOI https://dx.doi.org/10.2174/156802606777323782 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology The Use of Anthracyclines for Therapy of CNS Tumors
Anti-Cancer Agents in Medicinal Chemistry Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Innate Immune Receptors and IRF Family Transcription Factors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Electroporation Advances in Large Animals
Current Gene Therapy HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Prognostic Role of Hedgehog-GLI1 Signaling Pathway in Aggressive and Metastatic Breast Cancers
Current Drug Metabolism Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expressio
Current Protein & Peptide Science Recent Advances in Targeted Therapy for Glioma
Current Medicinal Chemistry Identification of KEY lncRNAs and mRNAs Associated with Oral Squamous Cell Carcinoma Progression
Current Bioinformatics Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research p53: A Guide to Apoptosis
Current Cancer Drug Targets